Mild Cognitive Impairment - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mild Cognitive Impairment - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Mild Cognitive Impairment - Pipeline Review, H1 2016', provides an overview of the Mild Cognitive Impairment pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
- The report reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Mild Cognitive Impairment therapeutics and enlists all their major and minor projects
- The report assesses Mild Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Mild Cognitive Impairment
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Mild Cognitive Impairment Overview 10
Therapeutics Development 11
Pipeline Products for Mild Cognitive Impairment - Overview 11
Pipeline Products for Mild Cognitive Impairment - Comparative Analysis 12
Mild Cognitive Impairment - Therapeutics under Development by Companies 13
Mild Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes 14
Mild Cognitive Impairment - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Mild Cognitive Impairment - Products under Development by Companies 18
Mild Cognitive Impairment - Products under Investigation by Universities/Institutes 20
Mild Cognitive Impairment - Companies Involved in Therapeutics Development 21
AbbVie Inc. 21
AgeneBio Inc. 22
Avraham Pharmaceuticals Ltd. 23
CereSpir Incorporated 24
D-Pharm Ltd. 25
Eisai Co., Ltd. 26
Eli Lilly and Company 27
Ensol Biosciences Inc. 28
Genzyme Corporation 29
Nanotherapeutics, Inc. 30
Neuron Biopharma SA 31
Octapharma AG 32
Sage Therapeutics, Inc. 33
Suven Life Sciences Ltd. 34
Takeda Pharmaceutical Company Limited 35
Therapix Biosciences Ltd 36
Mild Cognitive Impairment - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
ABT-957 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
BAN-2401 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CSP-1103 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DAOI-B - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DP-NDD - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
dronabinol - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
immune globulin (human) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ladostigil tartrate - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
levetiracetam - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LY-2599666 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LY-3002813 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Moriah-1000 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
NPS-0158 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
NSP-0163 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
NST-0037 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NST-0076 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
NST-0078 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NTC-942 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
pioglitazone hydrochloride - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
sargramostim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
sepranolone - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecule to Agonize GABRA5 Receptor for CNS Disorders - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for CNS Disorders - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SUVN-501 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SUVN-502 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SUVN-507 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SUVN-512 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
SUVN-976 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
tropisetron hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Mild Cognitive Impairment - Recent Pipeline Updates 84
Mild Cognitive Impairment - Dormant Projects 98
Mild Cognitive Impairment - Discontinued Products 100
Mild Cognitive Impairment - Product Development Milestones 101
Featured News & Press Releases 101
Jul 28, 2015: Avraham Pharmaceuticals Announces Successful Second Interim Results in Phase 2b Study of Ladostigil for the Treatment of Mild Cognitive Impairment 101
Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102
Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease 102
Jul 08, 2014: Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI 103
Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON 103
May 17, 2012: Avraham Initiates Phase II Ladostigil Study For Treatment Of Mild Cognitive Impairment 105
Apr 14, 2010: Alzheimer Drug Co Avraham Pharmaceuticals Raises $9m 105
Jul 27, 2009: Suven Presented Positive Phase-I Clinical Data Of SUVN-502 For Alzheimer's Disease At ICAD 2009, Vienna, Austria. 105
Apr 09, 2009: Suven Completes Phase I Clinical Trials Multiple Ascending Dose Of SUVN-502 In Switzerland 106
Oct 13, 2008: Suven Announces That SUVN-502 Data Is Being Presented At 16th BioPartnering In London 107
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 108
Disclaimer 109

List of Tables

Number of Products under Development for Mild Cognitive Impairment, H1 2016 11
Number of Products under Development for Mild Cognitive Impairment - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
Mild Cognitive Impairment - Pipeline by AbbVie Inc., H1 2016 21
Mild Cognitive Impairment - Pipeline by AgeneBio Inc., H1 2016 22
Mild Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H1 2016 23
Mild Cognitive Impairment - Pipeline by CereSpir Incorporated, H1 2016 24
Mild Cognitive Impairment - Pipeline by D-Pharm Ltd., H1 2016 25
Mild Cognitive Impairment - Pipeline by Eisai Co., Ltd., H1 2016 26
Mild Cognitive Impairment - Pipeline by Eli Lilly and Company, H1 2016 27
Mild Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H1 2016 28
Mild Cognitive Impairment - Pipeline by Genzyme Corporation, H1 2016 29
Mild Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H1 2016 30
Mild Cognitive Impairment - Pipeline by Neuron Biopharma SA, H1 2016 31
Mild Cognitive Impairment - Pipeline by Octapharma AG, H1 2016 32
Mild Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H1 2016 33
Mild Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H1 2016 34
Mild Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 35
Mild Cognitive Impairment - Pipeline by Therapix Biosciences Ltd, H1 2016 36
Assessment by Monotherapy Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Mild Cognitive Impairment Therapeutics - Recent Pipeline Updates, H1 2016 84
Mild Cognitive Impairment - Dormant Projects, H1 2016 98
Mild Cognitive Impairment - Dormant Projects (Contd..1), H1 2016 99
Mild Cognitive Impairment - Discontinued Products, H1 2016 100